Kepivance is a truncated human recombinant keratinocyte growth factor (KGF). KGF stimulates the growth of cells that line the surface of the mouth and intestinal tract. Kepivance reduces the incidence and duration of severe oral mucositis by protecting those cells and stimulating the growth of new epithelial cells to build up the mucosal barrier.
The campaign was successful, helping Amgen exceed forecasted sales in excess of $30 million
for the first half of 2006. Sales in 2009 were